论文部分内容阅读
目的 探讨介入治疗联合膀胱灌注丝裂霉素C(MMC)预防浅表性膀胱癌术后复发的临床价值。 方法 2 8例浅表性膀胱癌患者局部手术后随机分为二组 ,每组 14例。分别采用介入治疗加膀胱灌注MMC和MMC单纯膀胱灌注治疗。 结果 2 8例随访 12～ 2 6个月 ,平均 2 1个月。介入加灌注组肿瘤复发 1例 ,单纯MMC灌注组肿瘤复发 4例 ,两组肿瘤复发率差异有显著性意义 (P <0 .0 5 )。 结论 介入治疗联合膀胱灌注MMC预防浅表性膀胱癌术后复发疗效较好 ,副反应少 ,临床应用安全可靠
Objective To investigate the clinical value of interventional therapy combined with intravesical instillation of mitomycin C (MMC) in the prevention of postoperative recurrence of superficial bladder cancer. Methods Twenty-eight patients with superficial bladder cancer were randomly divided into two groups (14 in each group). Interventional therapy plus bladder MMC and MMC bladder irrigation were used respectively. Results 28 cases were followed up for 12 ~ 26 months with an average of 21 months. One case was involved in tumor recurrence in perfusion group, and 4 cases recurred in MMC-only group. There was significant difference in tumor recurrence rate between the two groups (P <0.05). Conclusion Interventional chemotherapy combined with intravesical instillation of MMC in preventing postoperative recurrence of superficial bladder cancer has better curative effect, fewer side effects and safe and reliable clinical application